Article

Cancer Genomic Profiling Identified Dihydropyrimidine Dehydrogenase Deficiency in Bladder Cancer Promotes Vulnerability to Gemcitabine

2022-02-15

Abstract excerpt

Chemotherapy is a standard therapy for muscle-invasive bladder cancer (MIBC). However, genomic alterations associated with chemotherapy sensitivity in MIBC have not been fully explored. This study aimed to investigate the genomic landscape of MIBC in association with the response to chemotherapy and to explore the biological role of genomic alterations. Genomic alterations in MIBC were sequenced by targeted exome...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 84bcb073-cf8b-5b10-b1e5-22f524d583e2
DOI: 10.21203/rs.3.rs-1322840/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cancer Genomic Profiling Identified Dihydropyrimidine Dehydrogenase Deficiency in Bladder Cancer Promotes Vulnerability to GemcitabineDOI 10.21203/rs.3.rs-1322840/v1Read

Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder CancerSemantic proximity Read

Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder CancerSemantic proximity Read

IDH2 stabilizes HIF‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancerSemantic proximity Read

Doctors revise Declaration of HelsinkiSemantic proximity Read

Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.Semantic proximity Read

Genomic Alterations of Signaling and DNA Damage Repair Pathways in Non-Muscle Invasive Bladder Cancer.Semantic proximity Read

Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients.Semantic proximity Read

Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylationSemantic proximity Read

Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine ResponseSemantic proximity Read

Significance of TP53 mutation in bladder cancer disease progression and drug selectionSemantic proximity Read

Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/DocetaxelSemantic proximity Read

Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.Semantic proximity Read